We will be at ECCMID 2019 with a poster contribution and as an exhibitor. The poster is on a novel cUTI mouse model and the application of PK/PD modelling to derive the required effect in the mouse model that translates to clinical response. We used historical Levofloxacin data to establish this animal-human translation. Visit us at our booth to learn more how we can support your preclinical, translational and clinical program with PK/PD modelling. … Read the rest
LYO-X joint the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) alliance, a strong Network of ~ 50 European biopharmaceutical companies committed to developing innovative products to fend-off antibiotic-resistant pathogens.
We have continuously expanded our support of biotech companies with PK/PD modelling and SystemsPharmacology to translate their antibiotics more effectively to patients. Helping biotechnology companies to succeed and bringing new antibiotics to patients is something we feel really committed to.
By joining BEAM we hope to help even more biotechs to bring their drugs to patients and to increase the awareness of PK/PD modelling as a tool for efficient antibiotics drug development.… Read the rest
LYO-X will give a lecture + hands on seminar on ‘In-silico Drug Development, Modelling & Simulation’ at the University of Freiburg for Pharmacy Master Students. This is together with Dr. Regenold GmbH who will be covering complementary topics on preclinical and clinical drug development . We are looking forward to engage the students and to give them a real world perspective on how in silicon methods are used today to develop novel drugs.… Read the rest
Automated skin lesion detection and severity classification using image analysis and machine learning. Unique opportunity to boost your career in Switzerland as an outstanding researcher. Application deadline: July 15. 2018. See our career website for more details.… Read the rest
Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood. Link to abstract
M. Machacek (1), L. Renaud (1), C. Kohl (2), M. Vercauteren (2), L. Remen (2), R. Welford (2). (1) LYO-X GmbH, Ringstrasse 9, 4123 Allschwil, Switzerland. (2) Idorsia Pharmaceuticals Limited, Hegenheimermattweg 91, 4123 Allschwil, Switzerland… Read the rest
Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen; LYO-X GmbH, Allschwil, Switzerland; Department of Internal Medicine, Charité-Universitätsmedizin, Berlin, Germany; Department for Hemato-Oncology, Comprehensive Cancer Center, Charité-University Medicine, Berlin, Germany; Medizinischen Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Georgia; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; Hannover Medical School, Hannover, Germany; Onkologie Praxis, Leer, Germany; Klinikum Ludwigsburg, Ludwigsburg, Germany; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany; Onkologie Praxis, Worms, Germany; Instutut für Radiologie, Berlin, Germany; University of Surrey, Surrey, United Kingdom; CellAct, Dortmund, Germany; CellAct Pharma GmbH, Dortmund, Germany. … Read the rest
Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek1, Lionel Renaud1, Sasa Dimitrijevic2, Debora Schmitz2, Elena Ivanova2, Karin Jorga3; 1LYO-X GmbH, Allschwil, Switzerland; 2PIQUR Therapeutics AG, Basel, Switzerland; 3Karin Jorga Life Science Consulting GmbH, Basel, Switzerland. J Clin Oncol 34, 2016 (suppl; abstr e14101).… Read the rest
LYO-X is sponsoring the LATSIS Symposium on Personalised Medicine to be held at the ETH Zurich June 27–29 2016. Personalised medicine has a number of quite attractive advantages. Treatments tailored to the individual patient, for example by therapy selection based on diagnostic tools or by individualised dosing, should improve the effect, lower side effects and lower costs by avoiding ineffective treatments. It appears to be an obvious solution given the situation we have today in the health care system. However, despite the advantages most drugs are still developed as a one-fits-all solution without any diagnostic tools.… Read the rest